Kairos Pharma to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Kairos Pharma will participate in the H.C. Wainwright 27th Annual Global Investment Conference, presenting at the meeting and hosting one-on-one meetings with management. The company's lead candidate, ENV105, targets CD105 to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. Kairos Pharma is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer.

Kairos Pharma Ltd (NYSE:HUN) saw its stock surge by 165% following the announcement of encouraging safety results from its ongoing Phase 2 clinical trial of ENV-105 in patients with metastatic castration-resistant prostate cancer. The interim safety review revealed that ENV-105, a novel CD105 antagonist, was well tolerated when used alongside the standard hormone therapy, apalutamide. Among the first ten patients enrolled, there were no dose-limiting toxicities or unexpected adverse effects, and side effects related to treatment were manageable through standard supportive care. Notably, no Grade 3 or 4 toxicities were observed [1].

John Yu, MD, CEO of Kairos Pharma, commented, "The favorable safety profile observed in this Phase 2 study is encouraging, as it validates our belief in ENV-105’s clinical potential and supports continued development in a patient population with limited effective treatment options" [1].

The ongoing randomized Phase 2 study plans to enroll a total of 100 participants and is currently active at Cedars-Sinai Medical Center, City of Hope, and Huntsman Cancer Center. This trial focuses on men whose prostate cancer has advanced despite prior hormone-based therapies [1].

Highlighting the medical need, Kairos Pharma pointed out that prostate cancer impacts roughly one million men annually in the U.S., many of whom develop resistance to existing hormone treatments. The company anticipates sharing interim efficacy results from this study in September 2025 [1].

Kairos Pharma is also participating in the H.C. Wainwright 27th Annual Global Investment Conference, presenting at the meeting and hosting one-on-one meetings with management. The company's lead candidate, ENV105, targets CD105 to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. Kairos Pharma is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer [2].

References:
[1] https://ih.advfn.com/market-news/article/12721/kairos-pharma-shares-surge-on-promising-safety-data-for-prostate-cancer-treatment
[2] https://www.marketscreener.com/quote/stock/KAIROS-PHARMA-LTD-175311270/news/Kairos-Pharma-Announces-Positive-Safety-Results-from-Phase-2-Trial-of-ENV-105-in-Advanced-Prostate-C-50511918/